JP2019514938A5 - - Google Patents

Download PDF

Info

Publication number
JP2019514938A5
JP2019514938A5 JP2018556902A JP2018556902A JP2019514938A5 JP 2019514938 A5 JP2019514938 A5 JP 2019514938A5 JP 2018556902 A JP2018556902 A JP 2018556902A JP 2018556902 A JP2018556902 A JP 2018556902A JP 2019514938 A5 JP2019514938 A5 JP 2019514938A5
Authority
JP
Japan
Prior art keywords
unsubstituted
alkylene
substituted
group
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018556902A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019514938A (ja
JP6993985B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/029805 external-priority patent/WO2017189829A1/en
Publication of JP2019514938A publication Critical patent/JP2019514938A/ja
Publication of JP2019514938A5 publication Critical patent/JP2019514938A5/ja
Application granted granted Critical
Publication of JP6993985B2 publication Critical patent/JP6993985B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018556902A 2016-04-27 2017-04-27 イソキノリン-3イル-カルボキサミドならびにその調製および使用の方法 Active JP6993985B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662328255P 2016-04-27 2016-04-27
US62/328,255 2016-04-27
PCT/US2017/029805 WO2017189829A1 (en) 2016-04-27 2017-04-27 Isoquinolin-3-yl carboxamides and preparation and use thereof

Publications (3)

Publication Number Publication Date
JP2019514938A JP2019514938A (ja) 2019-06-06
JP2019514938A5 true JP2019514938A5 (enExample) 2021-03-25
JP6993985B2 JP6993985B2 (ja) 2022-01-14

Family

ID=60157337

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018556902A Active JP6993985B2 (ja) 2016-04-27 2017-04-27 イソキノリン-3イル-カルボキサミドならびにその調製および使用の方法

Country Status (30)

Country Link
US (8) US10106527B2 (enExample)
EP (3) EP4559905A3 (enExample)
JP (1) JP6993985B2 (enExample)
KR (1) KR102374844B1 (enExample)
CN (1) CN109310690B (enExample)
AR (1) AR108325A1 (enExample)
AU (1) AU2017258193B2 (enExample)
CA (1) CA3022002A1 (enExample)
CL (2) CL2018003065A1 (enExample)
CO (1) CO2018012299A2 (enExample)
CY (1) CY1124302T1 (enExample)
DK (1) DK3448386T3 (enExample)
ES (1) ES2865374T3 (enExample)
HR (1) HRP20210607T1 (enExample)
HU (1) HUE054103T2 (enExample)
IL (1) IL262470B (enExample)
LT (1) LT3448386T (enExample)
MA (1) MA43619B1 (enExample)
MD (1) MD3448386T2 (enExample)
MX (1) MX385859B (enExample)
MY (1) MY198966A (enExample)
PE (1) PE20190326A1 (enExample)
PH (1) PH12018502258A1 (enExample)
PL (1) PL3448386T3 (enExample)
PT (1) PT3448386T (enExample)
RS (1) RS61879B1 (enExample)
SG (2) SG11201809301YA (enExample)
SI (1) SI3448386T1 (enExample)
SM (1) SMT202100224T1 (enExample)
WO (1) WO2017189829A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
WO2017079759A1 (en) 2015-11-06 2017-05-11 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-c]pyridines and their anti-inflammatory uses thereof
CA3119019C (en) 2015-12-10 2024-06-11 Ptc Therapeutics, Inc. Compounds and methods for treating huntington's disease
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
TW201803869A (zh) 2016-04-27 2018-02-01 健生藥品公司 作為RORγT調節劑之6-胺基吡啶-3-基噻唑
WO2017205536A2 (en) * 2016-05-24 2017-11-30 Genentech, Inc. Therapeutic compounds and uses thereof
MY199242A (en) 2016-06-01 2023-10-22 Samumed Llc Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide
MX2019010302A (es) 2017-03-30 2019-11-21 Hoffmann La Roche Isoquinolinas como inhibidores de hpk1.
EP4151627A1 (en) 2017-06-05 2023-03-22 PTC Therapeutics, Inc. Compounds for treating huntington's disease
CN111182898B (zh) 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
CN111163838B (zh) 2017-06-28 2023-03-28 Ptc医疗公司 用于治疗亨廷顿氏病的方法
US10604514B2 (en) 2017-10-19 2020-03-31 Samumed, Llc 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof
US10653688B2 (en) 2017-10-27 2020-05-19 Samumed, Llc 6-(6-membered heteroaryl and aryl)isoquinolin-3-yl carboxamides and preparation and use thereof
US10413537B2 (en) 2017-10-27 2019-09-17 Samumed, Llc 6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof
US10703748B2 (en) 2017-10-31 2020-07-07 Samumed, Llc Diazanaphthalen-3-yl carboxamides and preparation and use thereof
BR112020019373A2 (pt) 2018-03-27 2020-12-29 Ptc Therapeutics, Inc. Compostos para o tratamento da doença de hutington
CN112334450A (zh) 2018-06-18 2021-02-05 詹森药业有限公司 作为RORγt的调节剂的苯基和吡啶基取代的咪唑
US11034658B2 (en) 2018-06-18 2021-06-15 Janssen Pharmaceutica Nv Pyridinyl pyrazoles as modulators of RORγT
US10975057B2 (en) 2018-06-18 2021-04-13 Janssen Pharmaceutica Nv 6-aminopyridin-3-yl pyrazoles as modulators of RORgT
CN112566901A (zh) 2018-06-18 2021-03-26 詹森药业有限公司 作为RORγt的调节剂的苯基取代的吡唑类
IL279688B2 (en) 2018-06-27 2025-01-01 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
WO2020005882A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
KR20210038845A (ko) 2018-06-27 2021-04-08 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료를 위한 헤테로아릴 화합물
JP7386841B2 (ja) 2018-07-24 2023-11-27 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト イソキノリン化合物及びその使用
TW202024053A (zh) 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
TW202023558A (zh) 2018-10-03 2020-07-01 美商建南德克公司 8-胺基異喹啉化合物及其用途
EP3911317A2 (en) 2019-01-17 2021-11-24 BioSplice Therapeutics, Inc. Methods of treating cartilage disorders through inhibition of clk and dyrk
CA3139821A1 (en) 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
WO2021007378A1 (en) * 2019-07-11 2021-01-14 Ptc Therapeutics, Inc. Compounds for use in treating huntington's disease
WO2021004547A1 (en) * 2019-07-11 2021-01-14 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as inhibitors of hpk1
WO2021089395A1 (en) * 2019-11-08 2021-05-14 Nerviano Medical Sciences S.R.L. Gem-disubstituted heterocyclic compounds and their use as idh inhibitors
JPWO2021235293A1 (enExample) * 2020-05-20 2021-11-25
EP4238974A4 (en) * 2020-10-28 2024-10-23 Adlai Nortye Biopharma Co., Ltd. HIGH ACTIVITY WNT PATHWAY INHIBITOR COMPOUND
AU2021371136A1 (en) 2020-10-29 2023-05-11 Merck Sharp & Dohme Llc N-linked isoquinoline amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
CA3198317A1 (en) * 2020-11-10 2022-05-19 Kevin J. Wilson Compounds and uses thereof
TW202321244A (zh) * 2021-07-26 2023-06-01 大陸商杭州阿諾生物醫藥科技有限公司 一種Wnt通路抑制劑化合物
TW202334157A (zh) * 2022-01-29 2023-09-01 大陸商杭州阿諾生物醫藥科技有限公司 一種Wnt通路抑制劑化合物
WO2024022365A1 (zh) * 2022-07-28 2024-02-01 杭州阿诺生物医药科技有限公司 一种Wnt通路抑制剂化合物
WO2024238620A1 (en) * 2023-05-17 2024-11-21 Woolsey Pharmaceuticals, Inc. Methods of treating traumatic encephalopathy syndrome

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4164559A (en) 1977-09-21 1979-08-14 Cornell Research Foundation, Inc. Collagen drug delivery device
US4474752A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
GB9414139D0 (en) 1994-07-13 1994-08-31 Smithkline Beecham Plc Novel compounds
ES2131463B1 (es) 1997-04-08 2000-03-01 Lilly Sa Derivados de ciclopropilglicina con propiedades farmaceuticas.
DE19746287A1 (de) * 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
US6440102B1 (en) 1998-07-23 2002-08-27 Durect Corporation Fluid transfer and diagnostic system for treating the inner ear
DE19853299C2 (de) 1998-11-19 2003-04-03 Thomas Lenarz Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs
US6120484A (en) 1999-02-17 2000-09-19 Silverstein; Herbert Otological implant for delivery of medicament and method of using same
IL144977A0 (en) 1999-05-21 2002-06-30 Bristol Myers Squibb Co Pyrrolotriazine derivatives and pharmaceutical compositions containing the same
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US6967023B1 (en) 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
EP1277754B8 (en) 2000-04-27 2005-09-28 Astellas Pharma Inc. Imidazopyridine derivatives
JP2004536113A (ja) 2001-07-03 2004-12-02 カイロン コーポレイション チロシンキナーゼおよびセリン/スレオニンキナーゼのインヒビターとしてのインダゾールベンズイミダゾール化合物
US6648873B2 (en) 2001-09-21 2003-11-18 Durect Corp. Aural catheter system including anchor balloon and balloon inflation device
FR2831536A1 (fr) 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
IL161576A0 (en) 2001-10-26 2004-09-27 Aventis Pharma Inc Benzimidazoles and analogues and their use as protein kinases inhibitors
WO2003035005A2 (en) 2001-10-26 2003-05-01 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
ES2281633T3 (es) 2002-02-19 2007-10-01 Pfizer Italia S.R.L. Derivados triciclicos de pirazol, procedimiento para su preparacion y su uso como agentes antitumorales.
CA2476665A1 (en) 2002-02-19 2003-08-28 Pharmacia Corporation Tricyclic pyrazole derivatives for the treatment of inflammation
WO2003097610A1 (en) 2002-05-17 2003-11-27 Pharmacia Italia S.P.A. Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
CN1656079A (zh) 2002-05-31 2005-08-17 卫材株式会社 吡唑化合物和含有该化合物的药物组合物
WO2003101993A1 (en) 2002-06-04 2003-12-11 Neogenesis Pharmaceuticals, Inc. Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents
GB0218625D0 (en) 2002-08-10 2002-09-18 Astex Technology Ltd Pharmaceutical compounds
FR2845382A1 (fr) 2002-10-02 2004-04-09 Sanofi Synthelabo Derives d'indazolecarboxamides, leur preparation et leur utilisation en therapeutique
UA81453C2 (en) 2003-02-27 2008-01-10 Pyrazolopyridine derivates
GB0310867D0 (en) * 2003-05-12 2003-06-18 Novartis Ag Organic compounds
EP2256106B1 (en) 2003-07-22 2015-05-06 Astex Therapeutics Limited 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
US7008953B2 (en) 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
CN1829713A (zh) 2003-07-30 2006-09-06 辉瑞大药厂 3,5二取代的吲唑化合物、药物组合物和介导或抑制细胞增殖的方法
WO2005014554A1 (en) 2003-08-08 2005-02-17 Astex Therapeutics Limited 1h-indazole-3-carboxamide compounds as mapkap kinase modulators
AU2004289539C1 (en) 2003-11-14 2012-06-07 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
EP1532980A1 (en) 2003-11-24 2005-05-25 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
FR2867778B1 (fr) 2004-03-16 2006-06-09 Sanofi Synthelabo Utilisation de derives d'indazolecarboxamides pour la preparation d'un medicament destine au traitement et a la prevention du paludisme
WO2005092890A2 (en) 2004-03-25 2005-10-06 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
DE602005024677D1 (de) 2004-04-22 2010-12-23 Memory Pharm Corp Indole, 1h-indazole, 1,2-benzisoxazole, 1,2-benzoisothiazole, deren herstellung und verwendungen
MXPA06013250A (es) 2004-05-14 2007-02-28 Abbott Lab Inhibidores de quinasa como agentes terapeuticos.
US7452993B2 (en) 2004-07-27 2008-11-18 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
WO2006024945A1 (en) 2004-09-03 2006-03-09 Pfizer Inc. Pharmaceutical compositions comprising a cdk inhibitor
US20060116519A1 (en) 2004-11-17 2006-06-01 Agouron Pharmaceuticals, Inc. Synthesis of 5-bromo-4-methyl-pyridin-3-ylmethyl)-ethyl-carbamic acid tert-butyl ester
WO2006054143A1 (en) 2004-11-17 2006-05-26 Pfizer Inc. Polymorphs of {5-[3-(4,6-difluoro-1h-benzoimidazol-2-yl)-1h-indazol-5-yl]-4-methyl-pyridin-3-ylmethyl}-ethyl-amine
WO2006063302A2 (en) 2004-12-10 2006-06-15 Wyeth Variants of glycogen synthase kinase 3 and uses thereof
US20060142247A1 (en) 2004-12-17 2006-06-29 Guy Georges Tricyclic heterocycles
JP2008537684A (ja) 2005-01-24 2008-09-25 ニューロシステック コーポレイション 内耳およびその他の組織へ治療薬および/またはその他の薬剤を送達するための装置および方法
US7541367B2 (en) 2005-05-31 2009-06-02 Janssen Pharmaceutica, N.V. 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
TW200804338A (en) 2005-11-24 2008-01-16 Astrazeneca Ab New compounds
US20070248590A1 (en) 2005-12-02 2007-10-25 Sirtris Pharmaceuticals, Inc. Modulators of CDC2-like kinases (CLKS) and methods of use thereof
KR20080106284A (ko) 2006-03-23 2008-12-04 에프. 호프만-라 로슈 아게 치환된 인다졸 유도체, 이의 제조 및 약학적 제제로서의 용도
US8008481B2 (en) 2006-03-31 2011-08-30 Ericsson Anna M Indazole compounds
WO2007125405A2 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
US20080153810A1 (en) 2006-11-15 2008-06-26 Forest Laboratories Holdings Limited Indazole derivatives useful as melanin concentrating receptor ligands
EP1932830A1 (en) 2006-12-11 2008-06-18 The Genetics Company, Inc. Sulfonamides and their use as a medicament
DE602006021591D1 (de) 2006-12-11 2011-06-09 Genetics Co Inc Aromatische 1,4-DI-Carboxylamide und deren Verwendung
CA2672167C (en) 2006-12-14 2016-01-26 Bayer Schering Pharma Aktiengesellschaft Dihydropyridine derivatives useful as protein kinase inhibitors
WO2008124848A1 (en) 2007-04-10 2008-10-16 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US20100137394A1 (en) 2007-04-30 2010-06-03 Grenentech, Inc. Pyrazole inhibitors of wnt signaling
KR101486026B1 (ko) 2007-05-10 2015-01-22 도그우드 파마슈티컬스, 아이엔씨. 플루오렌, 안트라센, 잔텐, 디벤조수베론 및 아크리딘의 유도체 및 이의 용도
US8304408B2 (en) 2007-05-24 2012-11-06 The Regents Of The University Of California Wnt signaling inhibitors, and methods for making and using them
TW200908968A (en) 2007-05-29 2009-03-01 Sgx Pharmaceuticals Inc Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators
CN101790526A (zh) 2007-06-08 2010-07-28 雅培制药有限公司 用作激酶抑制剂的5-杂芳基取代的吲唑化合物
EP2157859A4 (en) 2007-06-19 2011-01-12 Takeda Pharmaceutical INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE
WO2009011850A2 (en) 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
US20100190736A1 (en) 2007-08-02 2010-07-29 Nerviano Medical Sciences S.R.L. Morpholinyl anthracycline derivative combined with protein kinase inhibitors
CN101821279A (zh) 2007-08-15 2010-09-01 赛特凯恩蒂克公司 某些化学个体、组合物和方法
US9259399B2 (en) 2007-11-07 2016-02-16 Cornell University Targeting CDK4 and CDK6 in cancer therapy
WO2009085226A2 (en) 2007-12-21 2009-07-09 Sirtris Pharmaceuticals, Inc. Inhibitors of cdc2-like kinases (clks) and methods of use thereof
KR101061599B1 (ko) 2008-12-05 2011-09-02 한국과학기술연구원 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
CN101440092B (zh) 2008-12-25 2010-11-17 浙江大学 2-吲唑-4-氮杂吲哚-5-氨基衍生物及制备和应用
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
JP2012520887A (ja) 2009-03-18 2012-09-10 シェーリング コーポレイション ジアシルグリセロールアシルトランスフェラーゼの阻害剤としての二環式化合物
JP2012521429A (ja) 2009-03-23 2012-09-13 メルク・シャープ・エンド・ドーム・コーポレイション 疼痛治療用のp2x3受容体アンタゴニスト
EP2456310A4 (en) 2009-07-23 2013-01-23 Univ Vanderbilt SUBSTITUTED BENZOIMIDAZOLSULFONAMIDES AND SUBSTITUTED INDOLSULFONAMIDES AS MGLUR4 POTENTIATORS
BR112012002942A2 (pt) 2009-08-10 2015-10-13 Epitherix Llc indazóis como inibidores da trilha de sinalização de wnt/b-catenina e empregos terapêuticos destes.
ES2835553T3 (es) 2009-08-10 2021-06-22 Biosplice Therapeutics Inc Inhibidores de indazol de la vía de señalización de Wnt y sus usos terapéuticos
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
US7998878B2 (en) 2009-11-20 2011-08-16 Eastman Kodak Company Method for selective deposition and devices
SMT201700581T1 (it) 2009-12-21 2018-01-11 Samumed Llc 1h-pirazolo[3,4-b]piridine e loro usi terapeutici
JP5739448B2 (ja) 2009-12-21 2015-06-24 アレイ バイオファーマ、インコーポレイテッド cFMS阻害剤としての置換N−(1H−インダゾール−4−イル)イミダゾ[1,2−a]ピリジン−3−カルボキサミド化合物
EP2552893B1 (en) 2010-03-31 2014-10-29 Actelion Pharmaceuticals Ltd. Antibacterial isoquinolin-3-ylurea derivatives
KR101792895B1 (ko) 2010-04-06 2017-11-02 피터 맥칼룸 캔서 인스티튜트 방사선 보호 화합물 및 방법
WO2012068589A2 (en) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
CA2817460A1 (en) 2010-12-17 2012-06-21 F. Hoffmann-La Roche Ag Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
CN102558173B (zh) * 2010-12-31 2015-05-20 广州源生医药科技有限公司 抑制wnt信号传导的化合物、组合物及其应用
US8889684B2 (en) 2011-02-02 2014-11-18 Boehringer Ingelheim International Gmbh Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
RU2014105624A (ru) 2011-08-12 2015-09-20 Ф. Хоффманн-Ля Рош Аг Соединения индазола, способ их применения и фармацевтическая композиция
HUE041576T2 (hu) * 2011-09-14 2019-05-28 Samumed Llc Indazol-3-karboxamid-származékok és alkalmazásuk Wnt/b-katenin szignalizáló útvonal inhibitorokként
WO2013169793A2 (en) * 2012-05-09 2013-11-14 Ipierian, Inc. Methods and compositions for tdp-43 proteinopathies
US9557993B2 (en) 2012-10-23 2017-01-31 Analog Devices Global Processor architecture and method for simplifying programming single instruction, multiple data within a register
US9908867B2 (en) 2013-01-08 2018-03-06 Samumed, Llc 3-(benzoimidazol-2-yl)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof
SG11201505446WA (en) 2013-01-16 2015-08-28 Signal Pharm Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
BR112016021626A2 (pt) 2014-03-20 2018-05-15 Samumed, Llc indazol-3-carboxamidas 5-substituídas e preparação e uso das mesmas
WO2016040182A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof
WO2016040184A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040188A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040185A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
WO2016040190A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040193A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040180A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040181A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
EP4086257A1 (en) 2016-09-30 2022-11-09 SRI International Dual clk/cdk1 inhibitors for cancer treatment
US20220062240A1 (en) 2018-06-26 2022-03-03 Biosplice Therapeutics, Inc. Methods of treating cancer using a clk inhibitor
WO2020150545A1 (en) 2019-01-17 2020-07-23 Samumed, Llc Pyrazole derivatives as modulators of the wnt/b-catenin signaling pathway

Similar Documents

Publication Publication Date Title
JP2014526510A5 (enExample)
JP2016504387A5 (enExample)
JP2021516674A5 (enExample)
JP2015512443A5 (enExample)
CN101679310B (zh) 作为Tie2激酶抑制剂的炔基嘧啶
CN102369187B (zh) 用作wnt信号调节剂的n-(杂)芳基、2-(杂)芳基取代的乙酰胺类
RU2016141088A (ru) 5-замещённые индазол-3-карбоксамиды и их получение и применение
CN106188045B (zh) 作为wnt信号传导抑制剂的化合物、组合物及其应用
JP2017508763A5 (enExample)
CN110573500B (zh) N-(氮杂芳基)环内酰胺-1-甲酰胺衍生物及其制备方法和应用
CN103124729B (zh) 作为Axl抑制剂的药物活性化合物
JP4171072B2 (ja) p38タンパク質キナーゼのインヒビターとしての置換窒素含有ヘテロ環
JP2015515989A5 (enExample)
CN111032647B (zh) 溶血磷脂酸受体1(lpar1)抑制剂化合物
RU2014144309A (ru) Индазольные ингибиторы сигнального пути wnt и их терапевтические применения
ES2911040T3 (es) Nuevos derivados de heteroaril amida como inhibidores selectivos de histona deacetilasa 1 y 2 (HDAC1/2)
JP2016500684A5 (enExample)
CN113637007A (zh) Rho激酶抑制剂
JP2009536161A5 (enExample)
WO2022166974A1 (zh) 吡啶并嘧啶酮类衍生物及其制备方法和用途
CN101528742A (zh) 取代的氨基吡唑并吡啶类及其盐、它们的制备及包含它们的药物组合物
CN105377837B (zh) 用作s100‑抑制剂的n‑(杂芳基)磺酰胺衍生物
JP5326108B2 (ja) Tie2阻害剤としての置換スルホキシミンおよびその塩、それを含む医薬組成物、それを調製する方法およびその使用
CN104884058A (zh) 作为crac通道抑制剂的基于吡唑基的甲酰胺ii
RU2018141395A (ru) Изохинолин-3-иловые карбоксамиды и их получение и применение